Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14026 - 14050 of 14871 in total
Sacituzumab tirumotecan is a recombinant humanized IgG1 anti-TROP2 monoclonal antibody conjugated to a topoisomerase I inhibitor.
Investigational
Sasanlimab is under investigation in clinical trial NCT06218069 (Immuno-pet Imaging Responses Administered Immune Checkpoint Inhibitor).
Investigational
Izokibep is under investigation in clinical trial NCT05623345 (Psoriatic Arthritis Study of Izokibep).
Investigational
Gotistobart is under investigation in clinical trial NCT05671510 (ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors).
Investigational
Investigational
Talsupram is a selective norepinephrine reuptake inhibitor (NRI). It was under research for the treatment of depression in 1960 and 1970 but it was never marketed. Talsupram presents a similar structure to citalopram.
Experimental
Matched Description: … It was under research for the treatment of depression in 1960 and 1970 but it was never marketed. …
Metralindole, also known as Inkazan, is similar in structure and pharmacology to pirlindole. It functions as a reversible inhibitor of monoamine oxidase A. In Russia, this drug was investigated for potential antidepressant activity.
Experimental
Matched Description: … Metralindole, also known as Inkazan, is similar in structure and pharmacology to pirlindole. …
SJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and Secondary Myelodysplastic Syndromes, among others.
Investigational
Matched Description: … Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and
Clinafloxacin is a fluoroquinolone antibacterial currently under research. It has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.
Investigational
Matched Description: … However, its approval and release have been halted due to the presence of serious side effects. …
Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery).
Investigational
Matched Description: … Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple …
Diminazene, also known as Diminazine, 4,4'-(Diazoamino)benzamidine, 4,4'-(1-triazene-1,3-diyl)bis-benzenecarboximidamide, diminazine aceturate, or Diminazene aceturate, is a trypanocidal agent. Major brands of Diminazene are Berenil, Pirocide, Ganasag, and Azidin. This substance is a solid. This compound belongs to the phenylhydrazines. These are compounds containing a phenylhydrazide moiety, which consists of a hydrazide substituent...
Experimental
Matched Description: … Major brands of Diminazene are Berenil, Pirocide, Ganasag, and Azidin. This substance is a solid. ... HTH-type transcriptional regulator QacR, trypsin-1, amiloride-sensitive amine oxidase [copper-containing], and
RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).
Investigational
Matched Description: … neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and
IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset. IPH 1101 is the most advanced drug candidate of the γδ T cell platform
Investigational
Vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.
Investigational
Experimental
Experimental
Experimental
Displaying drugs 14026 - 14050 of 14871 in total